People with diabetes who were taking GLP-1 drugs had a low but elevated risk of an age-related eye disease that can sometimes lead to blindness, adding to a short list of concerns about eye health in people taking the powerful medications, STAT’s Elizabeth Cooney reports, citing an observational study in JAMA Ophthalmology. Researchers found that after one year, more than twice as many people on GLP-1 drugs developed neovascular age-related macular degeneration compared to similar people who were not taking the drugs. Manufacturers of GLP-1 medications include Eli Lilly (LLY), Novo Nordisk (NVO), AstraZeneca (AZN), and Sanofi (SNY).
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Vaccine opponent hired by RFK Jr. searches CDC record for autism link, WSJ says
- Eli Lilly Stock (LLY) Gets Multiple Wall Street Downgrades
- Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls
- Eli Lilly downgraded to Hold from Buy at Erste Group
- Eli Lilly Stock (LLY) Grows Despite U.K. Warnings to Pregnant Women Over Weight Loss Jabs